首页> 外文期刊>Neuropsychopharmacology >Changes of Sleep Architecture, Spectral Composition of Sleep EEG, the Nocturnal Secretion of Cortisol, ACTH, GH, Prolactin, Melatonin, Ghrelin, and Leptin, and the DEX-CRH Test in Depressed Patients during Treatment with Mirtazapine
【24h】

Changes of Sleep Architecture, Spectral Composition of Sleep EEG, the Nocturnal Secretion of Cortisol, ACTH, GH, Prolactin, Melatonin, Ghrelin, and Leptin, and the DEX-CRH Test in Depressed Patients during Treatment with Mirtazapine

机译:米氮平治疗期间抑郁症患者的睡眠结构变化,睡眠脑电图谱变化,夜间分泌皮质醇,ACTH,GH,催乳素,褪黑素,Ghrelin和Leptin以及DEX-CRH测试

获取原文
       

摘要

The noradrenergic and specific serotoninergic antidepressant mirtazapine improves sleep, modulates hormone secretion including blunting of hypothalamic–pituitary–adrenocortical (HPA) activity, and may prompt increased appetite and weight gain. The simultaneous investigation of sleep electroencephalogram (EEG) and hormone secretion during antidepressive treatment helps to further elucidate these effects. We examined sleep EEG (for later conventional and quantitative analyses) and the nocturnal concentrations of cortisol, adrenocorticotropin (ACTH), growth hormone (GH), prolactin, melatonin and the key factors of energy balance, ghrelin, and leptin before and after 28 days of treatment of depressed patients (seven women, three men, mean age 39.94.2 years) with mirtazapine. In addition, a sleep EEG was recorded at day 2 and the dexamethasone–corticotropin-releasing hormone (DEX-CRH) test was performed to assess HPA activity at days -3 and 26. Psychometry and mirtazapine plasma concentrations were measured weekly. Already at day 2, sleep continuity was improved. This effect persisted at day 28, when slow-wave sleep, low-delta, theta and alpha activity, leptin and (0300–0700) melatonin increased, and cortisol and ghrelin decreased. ACTH and prolactin remained unchanged. The first two specimens of GH collected after the start of quantitative EEG analysis were reduced at day 28. The DEX-CRH test showed, at day 26, a blunting of the overshoot of ACTH and cortisol found at day -3. The Hamilton Depression score decreased from 32.17.3 to 15.56.7 between days -1 and 28. A weight gain of approximately 3kg was observed. This unique profile of changes is compatible with the action of mirtazapine at 5-HT-2 receptors, at presynaptic adrenergic alpha 2 receptors, at the HPA system, and on ghrelin and leptin.
机译:去甲肾上腺素能和特定的5-羟色胺能抗抑郁药米氮平改善睡眠,调节激素分泌,包括使下丘脑-垂体-肾上腺皮质激素(HPA)活性减弱,并可能促进食欲和体重增加。在抗抑郁治疗期间对睡眠脑电图(EEG)和激素分泌的同时研究有助​​于进一步阐明这些作用。我们检查了睡眠脑电图(用于以后的常规分析和定量分析),以及28天前后皮质醇,肾上腺皮质激素(ACTH),生长激素(GH),催乳素,褪黑激素的夜间浓度以及能量平衡,生长素释放肽和瘦素的关键因素米氮平治疗抑郁症患者(七名女性,三名男性,平均年龄39.94.2岁)的疗效。此外,在第2天记录了睡眠脑电图,并在第3天和第26天进行了地塞米松-促肾上腺皮质激素释放激素(DEX-CRH)测试,以评估HPA活性。每周测量一次心理测验和米氮平的血浆浓度。在第2天,睡眠连续性得到改善。当慢波睡眠,低δ,θ和α活性,瘦素和(0300-0700)褪黑激素增加,而皮质醇和生长素释放肽减少时,这种作用持续到第28天。 ACTH和催乳激素保持不变。开始定量脑电图分析后收集的GH的前两个标本在第28天减少。DEX-CRH测试显示,在第26天,第--3天发现的ACTH和皮质醇过冲减弱。在第-1天到28天之间,汉密尔顿抑郁评分从32.17.3降低到15.56.7。观察到体重增加约3kg。这种独特的变化与米氮平对5-HT-2受体,突触前肾上腺素能α2受体,HPA系统以及对生长素释放肽和瘦蛋白的作用兼容。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号